ROBOSENSE
13.3.2021 03:32:07 CET | Business Wire | Press release
RoboSense ( https://robosense.ai/ ) announced the launch of China’s first automotive-grade solid-state LiDAR production line and would start mass production and delivery of the automotive-grade solid-state LiDAR RS-LiDAR-M1 for contract projects in Q2 this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210312005303/en/
At the CES2021 in January this year, RoboSense has officially unveiled the SOP version of the automotive-grade LiDAR RS-LiDAR-M1, which features a slim design, excellent performance, and reliable point cloud quality. Since July last year, the RS-LiDAR-M1 has successively received a number of orders for mass-production vehicle models around the world, among which, the first customer was an OEM from North America. In December last year, the RS-LiDAR-M1 samples were shipped to this OEM customer in batches, and became the world's first mass-production-ready automotive-grade MEMS solid-state LiDAR delivered.
Two days ago, Inceptio released the self-driving system "Xuanyuan" equipped with RoboSense solid-state LiDAR, and the two parties announced the partnership that the mass-produced L3 heavy-duty freight truck equipped with "Xuanyuan" system will be launched on the market by the end of 2021.
As a world-leading smart LiDAR supplier, RoboSense has reached in-depth cooperation with Inceptio from 2019 to provide high-performance automotive-grade MEMS solid-state LiDAR RS-LiDAR-M1 for Inceptio’s "Xuanyuan" system, the first full-stack self-developed autonomous trucking system for mass production. Inceptio develops the ULRS (ultra-long-range sensing), ARC (adaptive robust control) and FEAD (fuel-efficient autonomous driving) algorithms, and the ULRS can make the system perceive an ultra-long distance of up to 1,000 meters with a margin of error standing below 5%.
In June 2019, Inceptio has worked with Dongfeng Trucks and SINOTRUK respectively to developed L3 autonomous heavy-duty trucks. By the end of 2021, the mass-produced L3 heavy-duty trucks equipped with Inceptio’s "Xuanyuan" system with RoboSense LiDAR inside will be delivered to clients.
About RoboSense
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. Market-oriented, the company provides customers with various Smart LiDAR perception system solutions, including the MEMS and Mechanical types LiDAR HWs, fusion HW unit, and the AI-based fusion systems. To date, RoboSense LiDAR systems have been widely applied to the future mobility, including autonomous driving passenger cars, RoboTaxi, RoboTruck, RoboBus, automated logistics vehicles and intelligent road by domestic and international autonomous driving technology companies, OEMs, and Tier1 suppliers. https://robosense.ai/
About Inceptio
Inceptio Technology was founded in April 2018, with an aim to build a nation-wide freight network using autonomous driving trucks.
We focus on the transformation of line-haul logistics by providing a more secure, efficient, and economical Transportation-As-A-Service (Taas) to logistic customers. This is to be achieved with our automotive grade L3/L4 autonomous driving software/ hardware, developed in collaboration with major automotive manufacturers, fully integrated with mass-produced heavy-duty freight trucks. With our advanced technology and seasoned operation team, we envision to develop the most trustworthy autonomous freight service network.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005303/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom